BNC105

Cat. No.:	HY-16114				
CAS No.:	945771-74-4				
Molecular Formula:	C ₂₀ H ₂₀ O ₇				
Molecular Weight:	372.37				
Target:	Microtubule/Tubulin				
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	2 years		
		-20°C	1 year		

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (67.14 mM; Need ultrasonic)						
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.6855 mL	13.4276 mL	26.8551 mL		
		5 mM	0.5371 mL	2.6855 mL	5.3710 mL		
	10 mM	0.2686 mL	1.3428 mL	2.6855 mL			
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent o Solubility: 2.5 mg/	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.71 mM); Suspended solution; Need ultrasonic and warming					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (6.71 mM); Suspended solution; Need ultrasonic and warming						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution						

DIOLOGICAL ACTIV	
Description	BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.
IC ₅₀ & Target	BNC105 exhibited excellent potency against a panel of different cancer cell lines with IC50 <1 nM for DU145, Calu-6, MDA-MB- 231 etc. The selectivity observed for BNC105 against activated over quiescent HUVECs was also observed in human aortic arterial endothelial cells (HAAECs). BNC105 also exhibited good potency toward the cisplatin resistant cell line A2780cis.

ΗÒ

-0

• Biochem Biophys Res Commun. 2020 Feb 18;S0006-291X(20)30008-5.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Flynn BL, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011 Sep 8;54(17):6014-27.

[2]. Kremmidiotis G, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010 Jun;9(6):1562-73.

[3]. Inglis DJ, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 2014;15(11):1552-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA